Iridex Corporation Announces Enrollment of First Patient in Landmark UK Study Evaluating MicroPulse Technology as an Adjunct to anti-VEGF Therapy for Diabetic Macular Edema
MOUNTAIN VIEW, Calif., June 24, 2025 - Iridex Corporation (Nasdaq: IRIX), a leading provider of laser-based medical systems, has announced the enrollment of the first patient in the DAME Trial, an independent, investigator-led study in the UK. This clinical trial aims to evaluate the effectiveness, safety, and cost-efficiency of incorporating MicroPulse® laser technology alongside anti-VEGF therapy for patients with severe diabetic macular edema $(DME.AU)$. The study, led by Professor Noemi Lois at Queen's University Belfast, seeks to determine whether adding subthreshold MicroPulse treatments can reduce the frequency of anti-VEGF injections while maintaining visual outcomes. The trial involves 264 participants across at least 20 clinical sites in the UK. Results of the study are yet to be presented, as the trial is in its early stages.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IRIDEX Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9472090-en) on June 24, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.